Kiromic BioPharma Reports Favorable Results at Six Weeks fro

Scans of this first patient in the second cohort show 8.5% reduction in tumor size

...

Related Keywords

Beverly Hills , Texas , United States , Houston , Pietro Bersani , Kiromic Biopharma , Afshin Eli Gabayan , Company Deltacel , Beverly Hills Cancer Center , Kiromic Biopharma Inc , Twitter , Linkedin , Securities Exchange , Gamma Deltat Cell , Medical Oncologist , Medical Director , Principal Investigator , Chief Executive Officer , Gamma Deltat Cell Infusions , Subjects With Stage , Non Small Cell Lung , Hills Cancer Center , Gamma Deltat Cells , Securities Exchange Act , Annual Report ,